Company / Operating Income
4D Molecular Therapeutics, Inc. Operating Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$187.8M
FY2025
5-year range
-$187.8M / -$56.7M
FY2021-FY2025
Trend
-66.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 5 consecutive years, from -$51M in FY2020 to -$188M in FY2025.
Based on SEC 10-K filings.
-$188M in FY2025.
Declined from -$110M to -$188M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 4D Molecular Therapeutics, Inc.'s operating income has declined for 5 consecutive years.
- In FY2025, operating income decreased 66.4% year-over-year.
- Peak operating income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$187.8M | -66.4% |
| FY2024 | -$112.9M | -2.6% |
| FY2023 | -$110.0M | -54.3% |
| FY2022 | -$71.3M | -25.9% |
| FY2021 | -$56.7M | -11.6% |
| FY2020 | -$50.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026